Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 22, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 130,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,537.5 pence per share; lowest price paid was 1,517 pence per share.
- Treasury Holdings (Settled): 497,621,327 shares (9.20% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,951,327 shares (10.14% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,908,598,310 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 130,000 shares on March 22, 2013. Consequently, the percentage of shares held in Treasury increased to 10.14% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (497,951,327 including unsettled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,908,598,310 shares in issue) for disclosure threshold assessments under FSA rules.
- Review the price paid per share (1,517 to 1,537.5 pence) against the market price on March 22, 2013.